Clinical Trial

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ in Type 1 diabetes (T1DM) compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-13.
Status change: Not Yet Recruiting → Recruiting 2025-10-10
Trial Details
NCT Number NCT06976619
Lead Sponsor Mayo Clinic
Conditions Type 1 Diabetes, Type 2 Diabetes
Enrollment 60 participants
Start Date 2025-10-03
Primary Completion 2028-10-30 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-14